Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Conditions
Brief summary
This trial studies the side effects and best dose of AVB-S6-500 when given together with durvalumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum therapy or has come back. Immunotherapy with AVB-S6-500 and durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Detailed description
PRIMARY OBJECTIVE: I. To determine toxicity profile of the combination of batiraxcept (AVB-S6-500) and durvalumab therapy. SECONDARY OBJECTIVES: I. To estimate objective response rate to combination AVB-S6-500 and durvalumab therapy. II. To estimate the median immune-related progression free survival (irPFS) as well as overall survival (OS) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 after treatment with combination durvalumab and AVB-S6-500. III. To investigate molecular and immunological changes associated with the combination of AVB-S6-500 and durvalumab; specifically to describe changes in T cell populations (including but not limited to CD3, CD8, CD4, FOXP3) and cell proliferation, as well as report changes in the proportion of macrophage phenotypes M1 and M2 (with phenotypic markers potentially including arginase1, CD11b, PDL-1, and CD206). EXPLORATORY OBJECTIVES: I. To evaluate blood and tissue based biomarkers for immune related adverse events and disease progression. II. To investigate impact and possible sensitization of pretreatment with AVB-S6-500 monotherapy on subsequent combination of durvalumab and AVB-S6-500. III. To evaluate for molecular and immunologic differences between pre-treatment with single agent AVB-S6-500 as compared to durvalumab. OUTLINE: This is a phase I, dose-escalation of batiraxcept, followed by a phase II study. In Phase I, patients receive both batiraxcept (intravenously \[IV\] over 60 minutes on days 1 and 15) and durvalumab (IV over 60 minutes on day 1) every cycle. In Phase II, patients are randomized to 1 of 2 arms. ARM I: Patients receive batiraxcept IV over 60 minutes on days 1, 15, and 29 of cycle 0, and on days 1 and 15 of subsequent cycles. Beginning cycle 1, patients also receive durvalumab IV over 60 minutes on day 1. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive durvalumab IV over 60 minutes on days 1 and 22 of cycle 0 and on day 1 of subsequent cycles. Beginning cycle 1, patients also receive batiraxcept IV over 60 minutes on days 1 and 15. Cycle 0 continues for 6 weeks and subsequent cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 weeks for at least 90 days.
Interventions
DRUGBatiraxcept
Given IV
BIOLOGICALDurvalumab
Given IV
Sponsors
Aravive Biologics Inc
AstraZeneca
M.D. Anderson Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to provide signed informed consent * Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up * Histology (reviewed at MD Anderson Cancer Center \[MDACC\]) showing recurrent high grade epithelial ovarian, peritoneal, or fallopian tube cancer * Platinum resistant or refractory disease as defined by progression of disease on a platinum-containing regimen or recurrence of disease within 180 days of previous platinum treatment * Have measurable disease based on modified RECIST 1.1. For the purposes of this study measurable disease is defined at least one target lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each target lesion must be \> 20 mm when measured by conventional techniques, including palpation, plain x-ray, computed tomography (CT), and magnetic resonance imaging (MRI), or \> 10 mm when measured by spiral CT. The target lesion must be distinct from other tumor areas selected for pre-treatment biopsies. Pre-treatment imaging must be performed within 4 weeks of starting therapy * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of \>= 12 weeks * Body weight \> 30 kg. Note: if subject's weight falls below 30 kg during study but the patient is otherwise eligible to continue investigational therapy the dose of durvalumab will be modified to be weight-based (20 mg/kg for the 1500 mg dose; modification is not required for 1120 mg dose) * Hemoglobin \>= 9.0 g/dL * Absolute neutrophil count (ANC) \> 1500/mm\^3 * Platelet count \>= 100 x 10\^9/L (\> 75,000/mm\^3) * Serum bilirubin =\< 1.5 x upper limit of normal (ULN) * This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \[SGPT\]) =\< 2.5 x ULN unless liver metastases are present, in which case it must be =\< 5 x ULN * Measured creatinine clearance (CL) \> 40 mL/min or calculated creatinine CL \> 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance * Evidence of post-menopausal status or negative serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women \< 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) * Women \>= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \> 1 year ago, had chemotherapy-induced menopause with last menses \> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy) * Patients must have no currently available standard of care treatment options
Exclusion criteria
* Participation in another clinical study with an investigational product (IP) during the last 28 days * Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study * Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) =\< 28 days prior to the first dose of study drug. If sufficient wash-out time has not occurred due to the schedule or pharmacokinetic (PK) properties of an agent, a longer wash-out period will be required, as agreed by AstraZeneca, Aravive, and the investigator * Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade \>= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria * Patients with grade \>= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the primary investigator * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician * Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment * Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable * History of allogenic organ transplantation * Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], diverticulitis \[with the exception of diverticulosis\], systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\]). The following are exceptions to this criterion: * Patients with vitiligo or alopecia; * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; * Any chronic skin condition that does not require systemic therapy; * Patients without active disease in the last 5 years may be included but only after consultation with the primary investigator; * Patients with celiac disease controlled by diet alone * Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring Adverse Events (AEs) or compromise the ability of the patient to give written informed consent * Any medical, social, or psychological condition that would interfere with evaluation of study treatment or interpretation of patient safety or study results * Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis \[TB\] testing in line with local practice), hepatitis B (known positive hepatitis B virus \[HBV\] surface antigen \[HBsAg\] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA) * History of another primary malignancy except for the following histories: * Malignancy treated with curative intent and with no known active disease \>= 5 years before the first dose of IP and of low potential risk for recurrence * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease * History of leptomeningeal carcinomatosis * Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have a magnetic resonance imaging (MRI) (preferred) or computed tomography (CT), each preferably with intravenous (IV) contrast of the brain prior to study entry * Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) \>= 470 ms * Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or AVB-S6-500. The following are exceptions to this criterion: * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection); * Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) * Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 90 days after the last dose of IP * Female patients who are pregnant or breastfeeding or of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + AVB-S6-500 combination therapy * Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients * Unresolved partial or complete small or large bowel obstruction * Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With Adverse Events | 35 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To Estimate Objective Response Rate to Combination AVB-S6-500 and Durvalumab Therapy | 35 months | — |
| To Estimate the Median Immune-related Progression Free Survival (irPFS) as Well as Overall Survival OS by RECIST 1.1 After Treatment With Combination Durvalumab and AVB-S6-500 | 35 months | — |
| To Investigate Molecular and Immunological Changes Associated With the Combination of AVBS6-500 and Durvalumab. | 35 months | Serum fractions will be isolated from blood samples collected in EDTA-free tubes and will be used to measure GAS6 suppression, which will be analyzed by Altasciences. |
Countries
United States
Participant flow
Recruitment details
The study recruitment was from December 2019 until November 2022 and all recruitments were done in a medical clinic setting.
Participants by arm
| Arm | Count |
|---|---|
| Phase 1 Durvalumab 1500 mg IV every 4 weeks + AVB-S6-500 10 mg/kg IV every 2 weeks | 11 |
| Phase 2A Monotherapy with AVB-S6-500 IV 10 mg/kg every 2 weeks for 6 weeks then combination of Durvalumab 1500 mg IV every 4 weeks + AVB-S6-500 10 mg/kg IV every 2 weeks | 0 |
| Phase 2D Monotherapy with Durvalumab 1500 mg IV every 4 weeks for 6 weeks then combination of Durvalumab 1500 mg IV every 4 weeks + AVB-S6-500 10 mg/kg IV every 2 weeks | 0 |
| Total | 11 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Phase 1 | Total |
|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants | 10 Participants |
| Age, Continuous | 56.9 years | 56.9 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 9 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 2 Participants |
| Race (NIH/OMB) White | 8 Participants | 8 Participants |
| Region of Enrollment United States | 11 participants | 11 participants |
| Sex: Female, Male Female | 11 Participants | 11 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 11 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 11 / 11 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 3 / 11 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Number of Participants With Adverse Events
Time frame: 35 months
Population: Treatment never progressed passed phase 1.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Phase 1 | Number of Participants With Adverse Events | Grade 1 AEs | 11 participants |
| Phase 1 | Number of Participants With Adverse Events | Grade 2 AEs | 9 participants |
| Phase 1 | Number of Participants With Adverse Events | Grade 3 AEs | 3 participants |
| Phase 1 | Number of Participants With Adverse Events | Grade 2 SAEs | 2 participants |
| Phase 1 | Number of Participants With Adverse Events | Grade 3 SAEs | 1 participants |
Secondary
To Estimate Objective Response Rate to Combination AVB-S6-500 and Durvalumab Therapy
Time frame: 35 months
Population: Treatment never progressed passed phase 1.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1 | To Estimate Objective Response Rate to Combination AVB-S6-500 and Durvalumab Therapy | 11 Participants |
Secondary
To Estimate the Median Immune-related Progression Free Survival (irPFS) as Well as Overall Survival OS by RECIST 1.1 After Treatment With Combination Durvalumab and AVB-S6-500
Time frame: 35 months
Population: Treatment never progressed passed phase 1.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase 1 | To Estimate the Median Immune-related Progression Free Survival (irPFS) as Well as Overall Survival OS by RECIST 1.1 After Treatment With Combination Durvalumab and AVB-S6-500 | PFS | 1.81 Months |
| Phase 1 | To Estimate the Median Immune-related Progression Free Survival (irPFS) as Well as Overall Survival OS by RECIST 1.1 After Treatment With Combination Durvalumab and AVB-S6-500 | OS | 4.53 Months |
Secondary
To Investigate Molecular and Immunological Changes Associated With the Combination of AVBS6-500 and Durvalumab.
Serum fractions will be isolated from blood samples collected in EDTA-free tubes and will be used to measure GAS6 suppression, which will be analyzed by Altasciences.
Time frame: 35 months
Population: Treatment never progressed passed phase 1.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1 | To Investigate Molecular and Immunological Changes Associated With the Combination of AVBS6-500 and Durvalumab. | 30.5 ng/mL |